Glucocorticoid receptor blockage and thymidine phosphorylase inhibition: a new treatment option for psoriasis

Aruna V.; Gayathri Rajagopal; Ranganathan S.

doi:10.18203/issn.2455-4529.IntJResDermatol20253392

Authors

Aruna V. Department of Research and Development, Dr. JRK’s Research and Pharmaceutical Pvt. Ltd., Kundrathur, Chennai, Tamil Nadu, India
Gayathri Rajagopal Department of Research and Development, Dr. JRK’s Research and Pharmaceutical Pvt. Ltd., Kundrathur, Chennai, Tamil Nadu, India
Ranganathan S. Department of Research and Development, Dr. JRK’s Research and Pharmaceutical Pvt. Ltd., Kundrathur, Chennai, Tamil Nadu, India

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20253392

Keywords:

Psorolin B, Boswellic acid, GR receptor, KU812, Thymidine phosphorylase

Abstract

Background: The present study describes the efficacy of an ointment widely used in the treatment of psoriasis blocking glucocorticoid (GR) receptor in KU812 cells.

Methods: The ointment is composed of various phyto-actives source from the botanicals such as Wrightia tinctoria, Cynodon dactylon, Boswellia serrata, and Hydnocarpus laurifolia.

Results: The present findings clearly demonstrate the ointment having steroid-like effect essential for the treatment of psoriasis. The steroid like effect would hinder/reduce the inflammatory events, the major clinical manifestation in psoriasis. Further the ointment also has exhibited effect in inhibiting thymidine phosphorylase (TP) activity and thereby prevent/reduce the events that lead to angiogenesis and flow pro-inflammatory mediators at the site of lesion. Angiogenesis is one of the early changes that prelude inflammatory cascade.

Conclusions: The dual efficacy of the ointment viz., blocking GR and inhibiting TP enzyme and thereby suppressing angiogenesis clearly indicate the essential therapeutic effect of the ointment for the treatment of psoriasis.

Metrics

Metrics Loading ...

References

Ten Bergen LL, Petrovic A, Aarebrot AK, Appel S. Current knowledge on autoantigens and autoantibodies in psoriasis. Scand J Immunol. 2020;92(4):e12945. DOI: https://doi.org/10.1111/sji.12945

Ortiz-Lopez LI, Choudhary V, Bollag WB. Updated Perspectives on Keratinocytes and Psoriasis: Keratinocytes are More Than Innocent Bystanders. Psoriasis (Auckl). 2022;12:73-87. DOI: https://doi.org/10.2147/PTT.S327310

Anthoni C, Laukoetter MG, Rijcken E, Vowinkel T, Mennigen R, Müller S, et al. Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2006;290(6):G1131-7. DOI: https://doi.org/10.1152/ajpgi.00562.2005

Schleimer RP, MacGlashan DW Jr, Gillespie E, Lichtenstein LM. Inhibition of basophil histamine release by anti-inflammatory steroids. II. Studies on the mechanism of action. J Immunol. 1982;129(4):1632-6. DOI: https://doi.org/10.4049/jimmunol.129.4.1632

Sengupta S, Sellers LA, Matheson HB, Fan TP. Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms. Br J Pharmacol. 2003;139(2):219-31. DOI: https://doi.org/10.1038/sj.bjp.0705216

Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol. 2009;90(3):232-48. DOI: https://doi.org/10.1111/j.1365-2613.2009.00669.x

Hammerberg C, Fisher GJ, Voorhees JJ, Cooper KD. Elevated thymidine phosphorylase activity in psoriatic lesions accounts for the apparent presence of an epidermal “growth inhibitor,” but is not in itself growth inhibitory. J Investig Dermatol. 1991;97(2):286-90. DOI: https://doi.org/10.1111/1523-1747.ep12480547

Creamer D, Jaggard R, Allen M, Bicknell R, Barker J. Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol. 1997;137(6):851-5. DOI: https://doi.org/10.1111/j.1365-2133.1997.tb01543.x

Hara T, Yamada K, Tachibana H. Basophilic differentiation of the human leukemia cell line KU812 upon treatment with interleukin-4. Biochem Biophys Res Commun. 1998;247(3):542-8. DOI: https://doi.org/10.1006/bbrc.1998.8816

Ebo DG, Bridts CH, Mertens CH. Analyzing histamine release by flow cytometry (HistaFlow): A novel instrument to study the degranulation patterns of basophils. J Immunol Methods. 2012;375(1-2):30-8. DOI: https://doi.org/10.1016/j.jim.2011.09.003

Javaid S, Shaikh M, Fatima N, Choudhary MI. Natural compounds as angiogenic enzyme thymidine phosphorylase inhibitors: In vitro biochemical inhibition, mechanistic, and in silico modeling studies. PLoS One. 2019;14(11):e0225056. DOI: https://doi.org/10.1371/journal.pone.0225056

Amruthavalli GV. An open-label, randomized clinical trial of Psorolin B ointment in the treatment of plaque psoriasis. Dermatol Res Skin Care. 2024;8(1):186.

Katragunta K, Siva B, Kondepudi N, Vadaparthi PRR, Rao NR, Tiwari AK, et al. Estimation of boswellic acids in herbal formulations containing Boswellia serrata extract and comprehensive characterization of secondary metabolites using UPLC-Q-Tof-MSe. J Pharm Anal. 2019;9(6):414-22. DOI: https://doi.org/10.1016/j.jpha.2019.09.007

Aruna V, Amruthavalli GV, Rajakumar S, Rajagopal G. Possible steroidal effect of Boswellia serrata and homeostasis of Histidine-HDC-Histamine in psoriasis. J Med Res Health Sci. 2022;5(11):2324-8.

Aruna V, Amruthavalli GV, Rajagopal G. Modulation of S100A7 on KC surface and associated immune deflection: Psorolin B ointment. Int J Dermatol Venereol Leprosy Sci. 2024;7(1):32-36. DOI: https://doi.org/10.33545/26649411.2024.v7.i1a.178

Amruthavalli GV, Aruna V, Rajagopal G. Psorolin B: A formulation with synchronized, synergistic scooping of botanicals and associated exodus therapeutic benefit to psoriasis. Int J Res Dermatol. 2022;8:85-9. DOI: https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20214918